September 15, 2006
SOLVO Biotechnology has significantly expanded its Contract Screening portfolio offering now a unique integrated service platform to evaluate the membrane transporter profiles of drug candidates at various pharmacological barriers and transporter mediated drug-drug interactions.SOLVO services include not only the standard Monolayer assays, but it focuses also on all the major efflux and uptake transportersindividual HTS assay systems for each transporter that enablesthe in depth analysis of tranporter-drug and transporter mediated drug-drug interactions.
Comprehensive Contract Research Services: cover the following assays
Efflux Transporter Assays |
|
ATPase Assays |
human Pgp / MDR1 (ABCB1) rat Mdr1b human MRP1 (ABCC1) human MRP2 (ABCC2) rat Mrp2 human MRP3 (ABCC3) human BCRP / MXR (ABCG2) |
Vesicular Transport Assays |
human MRP1 (ABCC1) human MRP2 (ABCC2) human MRP3 (ABCC3) human MRP5 (ABCC5) human BCRP / MXR (ABCG2) human BSEP / sPgp (ABCB11) mouse bsep
Under development:
human MRP6 mouse Bcrp rat Bsep ABCA1, ABCG5/G8 |
Cellular Dye Transport Assays |
human Pgp / MDR1 (ABCB1) human MRP1 (ABCC1) human BCRP / MXR (ABCG2) |
Whole Cell Assays |
Uptake Transporter Assays: |
rat Ntcp human OATP1B1 (OATP2, OATP-C) human OATP1B3 (OATP8) human OATP2B1 (OATP-B) rat Oatp1a1 (Oatp1)
Under development:
human NTCP (SLC10A1) rat Oatp2 (Oatp1a4) rat Oatp4(Oatp1b2) human PEPT1 (SLC15A1) human PEPT2 (SLC15A2) |
Monolayer Permeability Assays: |
Unidirectional permeability of the test compound on Caco2 cells. Unidirectional permeability of the test compound on MDCKII (parental) cells. Unidirectional permeability of the test compound on Caco2 cells in the presence of specific inhibitors. Bidirectional permeability of the test compound on Caco2 cells. Bidirectional permeability of 3H-digoxin in the presence of the test compound (PgP DDI model). |
Extensive Service Development Pipeline: In the next 18 months SOLVO will establish and validate a complex Pharmacokinetic Technological Platform that integrates, correlates and harmonizes DMPK and ADME-Tox (in vitro, ex vivo and in vivo) research systems including the following elements:
Most major pharmaceutical and biotechnology companies utilize our products and services in their drug discovery development pipeline.
For further information and a detailed research proposal please contact SOLVO Biotechnology.
Best regards,
SOLVO Biotechnology
Business Development Team
Next entry: Dr. Karl Kuchler joins SOLVO Strategic Advisory Board
Previous entry: Introducing mouse Bsep and MRP5 vesicular transport assays